Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run (NASDAQ:VTRS)
· seekingalpha.com
Viatris is rated a Sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. Read more on VTRS stock here.
Viatris Inc. ( VTRS ) is a large-cap ($20 billion market cap) pharmaceutical company specializing in generics and off-patent legacy brands. It was founded in 20...